D
David J. Hosking
Researcher at University of Nottingham
Publications - 134
Citations - 10711
David J. Hosking is an academic researcher from University of Nottingham. The author has contributed to research in topics: Osteoporosis & Bone remodeling. The author has an hindex of 48, co-authored 134 publications receiving 10354 citations. Previous affiliations of David J. Hosking include University of Texas Health Science Center at San Antonio & Nottingham City Hospital.
Papers
More filters
Journal ArticleDOI
Management of male osteoporosis: report of the UK Consensus Group.
Richard Eastell,I.T. Boyle,Juliet E. Compston,C. Cooper,Ignac Fogelman,Roger M. Francis,David J. Hosking,D. W. Purdie,S. H. Ralston,J. Reeve,David M. Reid,Roslin Russell,J. C. Stevenson +12 more
TL;DR: Osteoporosis can be diagnosed on the basis of radiological assessments of bone mass, or clinically when it becomes symptomatic, and agents to influence bone resorption or formation and specific therapy for any underlying pathological condition are offered.
Journal ArticleDOI
Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial
Ian R. Reid,Geoffrey C. Nicholson,Robert S. Weinstein,David J. Hosking,Tim Cundy,Mark A. Kotowicz,William A. Murphy,Swan Yeap,Suzanne Dufresne,Antonio Lombardi,Thomas Musliner,Desmond E. Thompson,A. John Yates +12 more
TL;DR: Oral alendronate appears to be a safe and effective therapy for Paget's disease and results in healing of lytic bone lesions.
Journal ArticleDOI
Vitamin D insufficiency increases bone turnover markers and enhances bone loss at the hip in patients with established vertebral osteoporosis.
TL;DR: Whether the presence of vitamin D insufficiency increases bone turnover and enhances bone loss is investigated by examining the relationship between bone turnover markers and Bone mineral density in vitamin D insufficient and vitamin D sufficient patients, with established vertebral osteoporosis.
Journal ArticleDOI
Vitamin D status in renal transplant recipients.
Aristeidis Stavroulopoulos,Michael J.D. Cassidy,Christine J. Porter,David J. Hosking,Simon D. Roe +4 more
TL;DR: 25‐OHD was low in virtually all of the renal transplant recipients and may aggravate secondary hyperparathyroidism, but its correction may be difficult in patients with hypercalcaemia.
Journal ArticleDOI
Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
David J. Hosking,Kenneth W. Lyles,Jacques P. Brown,William D. Fraser,Paul Miller,Manuel Diaz Curiel,Jean-Pierre Devogelaer,M. Hooper,Guoqin Su,K. Zelenakas,Judy Pak,T. Fashola,Y. Saidi,Erik Fink Eriksen,Ian R. Reid +14 more
TL;DR: A single 5‐mg infusion of zoledronic acid restores biochemical markers of bone turnover into the reference range in the majority of patients with Paget's disease and maintains biochemical remission for at least 2 years.